



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

24th March 2025

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received a Final Order from the ACIT Cir 7(1)(1) with the Demand Liability of Rs 23.21 Crores. The relevant details to be disclosed are as under:

Sr no	Particulars	Details
1	Name of the authority	Demand Liability issued by CPC of Rs INR 23.21 Crore for the AY: 2023-2024.
2	Nature and details of the action(s) taken, initiated or order(s) passed	The said Demand is received post the scrutiny assessment for the AY: 23-24.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Assessment Order dated 23 rd March, 2026 received on 24 th March, 2026 from CPC.
4	Details of violation(s) / contravention(s) committed or alleged to be committed	N.A.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Company is contesting the assessment order and is in the process of filing an appeal before the appellate authority. At present, there is no impact on the financial statements.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151